Chromosomal proteins regulate steroid binding to chromatin

Association of AlkB homolog 3 expression with tumor recurrence and unfavorable prognosis in hepatocellular carcinoma

BACKGROUND AND AIM

The mammalian AlkB homolog protein family has been reported to promote tumor cell invasion and metastasis of human cancer. However, the expression status and clinical significance of AlkB homolog 3 (ALKBH3) in hepatocellular carcinoma (HCC) have not been reported yet.

METHODS

In the present study, we investigated the protein expression of ALKBH3 by immunohistochemistry assay and evaluated its association with tumor progression, recurrence, and prognosis in 272 patients with HCC. In addition, we explored ALKBH3 function via gene overexpression and knockdown of ALKBH3.

RESULTS

AlkB homolog 3 was overexpressed in HCC compared with adjacent non-tumorous specimens. Moreover, ALKBH3 expression was closely related to tumor differentiation and tumor-node-metastasis stage. Interestingly, the ALKBH3 high expression in tumor tissues of HCC patients had more poor disease-free survival and overall survival than low-expression patients. Consistently, we found that knockdown of ALKBH3 inhibits HCC cell proliferation in vitro and xenograft tumor formation in vivo and overexpressing ALKBH3 showed the opposite results. ALKBH3 knockdown may inhibit cell proliferation, presumably through p21/p27-mediated cell-cycle arrest at G1 phase in human HCC. ALKBH3 may also play some role on chemosensitivity to certain genotoxic reagents, such as cisplatin (CDDP) and epirubicin.

CONCLUSIONS

These findings reveal an important role of ALKBH3 in HCC, indicating that ALKBH3 could be used as a new therapeutic target in future.

Submicroscopic interstitial deletion of chromosome 11q22.3 in a girl with mild mental retardation and facial dysmorphism: Case report

BACKGROUND

Except for terminal deletions that lead to Jacobsen syndrome, interstitial deletions involving the long arm of chromosome 11 are not frequently reported. A clinically distinct phenotype is usually observed in these cases, and no clear genotype-phenotype correlation is proposed.

RESULTS

Here we present a case study of a 5-year-old girl with de novo submicroscopic deletion of chromosome 11q22.3 with mild mental retardation and facial dysmorphism. A standard cytogenetic analysis did not reveal any structural aberrations. In contrary, array-CGH analysis indicated a small deletion of 11q22.3.

DISCUSSION

To our knowledge, this is the smallest 11q22.3 deletion reported in literature, containing nine RefSeq genes. Although none of the deleted genes are obvious candidates for the features observed in our patient, genes CUL5 and SLN could play a key role in the features described.

Interactions of the nuclear matrix-associated steroid receptor binding factor with its DNA binding element in the c-myc gene promoter

Steroid receptor binding factor (RBF) was originally isolated from avian oviduct nuclear matrix. When bound to avian genomic DNA, RBF generates saturable high-affinity binding sites for the avian progesterone receptor (PR). Recent studies have shown that RBF binds to a 54 bp element in the 5'-flanking region of the progesterone-regulated avian c-myc gene, and nuclear matrix-like attachment sites flank the RBF element [Lauber et al. (1997) J. Biol. Chem. 272, 24657-24665]. In this paper, electrophoretic mobility shift assays (EMSAs) and S1 nuclease treatment are used to demonstrate that the RBF-maltose binding protei (MBP) fusion protein binds to single-stranded DNA of its element. Only the N-terminal domain of RBF binds the RBF DNA element as demonstrated by southwestern blot analyses, and by competition EMSAs between RBF-MBP and the N-terminal domain. Mass spectrometric analysis of the C-terminal domain of RBF demonstrates its potential to form noncovalent protein-protein interactions via a potential leucine-isoleucine zipperlike structure, suggesting a homo- and/or possible heterodimer structure in solution. These data support that the nuclear matrix binding site (acceptor site) for PR in the c-myc gene promoter is composed of RBF dimers bound to a specific single-stranded DNA element. The dimers of RBF are generated by C-terminal leucine zipper and the DNA binding occurs at the N-terminal parallel beta-sheet DNA binding motif. This complex is flanked by nuclear matrix attachment sites.

Oestrogen receptors and cardiovascular disease

1. Animal and human studies indicate that female sex hormones are protective against the development of coronary atherosclerosis. 2. Experiments on vascular smooth muscle cells suggest a direct effect of oestrogen on vascular tissue. Although oestrogen receptors (ER) in vascular tissues and an association between ER stimulation and physiological effects have been demonstrated, the cellular mechanisms underlying the effects of oestrogen on the arterial wall remain to be defined. 3. Elucidation of the cellular mechanism underlying the effects of oestrogen on vascular smooth muscle will provide insights into coronary atherosclerosis and will provide an opportunity to apply the protective effects of oestrogen to women in older age groups and to the male population.

Nuclear acceptor sites for estrogen-receptor complexes in the liver of the turtle, Chrysemys picta. I. Sexual differences, species specificity and hormonal dependency

Hepatic estrogen receptors (ERs) of the female turtle, Chrysemys picta, when complexed with [3H]estradiol ([3H]E2), were shown to bind specifically to liver chromatin isolated from the same species. The binding of the [3H]E2 receptor complex to chromatin requires both the steroid ligand and the receptor protein. Maximal binding occurred within 60-70 min of incubation at 4 degrees C in a Tris buffer containing 0.1 M KCl. The binding of the [3H]E2 receptor complex to intact chromatin was saturable, whereas the binding to turtle or calf thymus DNA remained linear. Scatchard analyses revealed more estrogen receptor binding sites on hepatic chromatin isolated from female turtles than that prepared from the males (binding capacities: female chromatin = 67.9 +/- 6.8 fmol/mg DNA equivalent; male chromatin = 28.5 +/- 2.5 fmol/mg DNA equivalent). Furthermore, the [3H]E2 receptor complex was bound with a higher affinity to female chromatin than to male chromatin (association constants: female chromatin = 11.7 +/- 2.7 X 10(10) M-1; male chromatin = 2.5 +/- 0.7 X 10(10) M-1). In contrast to turtle hepatic [3H]E2 receptors, ERs in rat liver or mouse uterine cytosol exhibited little binding affinity for hepatic chromatin isolated from the turtle. Tissue specificity was demonstrated in the interaction of the [3H]E2 receptor complex and chromatin; high affinity, saturable binding of the [3H]E2 receptor complex was only observed on chromatin isolated from the liver but not on those prepared from the heart, kidney and muscle. A 3- to 4-fold increase in the number of hepatic chromatin [3H]E2 receptor binding sites was observed in 21-day ovariectomized or hypophysectomized female (capacities = 209.3 +/- 6.1 and 270 +/- 10.1 fmol/mg DNA equivalent, respectively). It is postulated that [3H]E2 receptor binding sites on the chromatin of intact females are partially 'masked', and removal of a gonadal and/or pituitary factor(s) unveils additional binding sites on the female chromatin. This paper is first to report the presence of high affinity, species- and tissue-specific acceptor sites on the liver chromatin of a reptilian species. The fact that the levels and properties of these acceptor sites are dependent on the sex and hormonal state of the animal suggests that they may play a role in the regulation of hepatic estrogen responsiveness and vitellogenesis in this species.

Relationship between changes of the steroid receptor and synchronization in human endometrial adenocarcinoma cells in vitro

It has been reported that the response of target cells to steroid hormone (SH) stimulation may depend on their position in the cell cycle. The DNA and RNA contents of malignant cells of the endometrium cultured in vitro were measured using flow cytometry (FCM). We also measured estrogen receptor (ER) and progesterone receptor (PR) levels of cells at different positions in the cell cycle. The G1 and S phases of the cell cycle were investigated using cells synchronized by sodium n-butyrate (G1 block), methotrexate (S block), and excess thymidine (S block). For DNA measurements, the cells were stained with propidium iodide following RNase treatment. For RNA measurements (double-stranded RNA) the cells were treated with DNase. We found that S phase synchronization by methotrexate was 136.2% of control (100%). Using the excess thymidine block and release procedure, the S phase fraction was 185.1% of control. G1 phase synchronization by sodium n-butyrate was 134% of control. The estrogen receptor level in G1 phase synchronized cells increased to 5.94 fmol/micrograms DNA in the cytosol and 12.35 fmol/micrograms DNA in the nuclear fraction. These levels represent a sevenfold total increase over that of the control estrogen receptor level. Cells in S phase showed no significant increase in estrogen receptor levels over control cells. Based on this study, the functional increase of the steroid receptor was most significant in the G1 phase.

Nuclear acceptor sites for steroid hormone receptors: comparisons of steroids and antisteroids

The respective chromatin binding sites (acceptor sites) for both the avian oviduct progesterone receptor (PR) and the rabbit uterine estrogen receptor (ER) reported by two separate laboratories are compared. Support for a saturable, high affinity binding to the chromatin acceptor sites by both receptors is described. Nonradiolabelled PR or ER compete with their homologous radiolabelled receptors for binding. However, there is no competition between the heterologous ER and PR for the nuclear binding sites. In both receptor systems, evidence for a receptor dependent, receptor specific binding, which mimics the binding measured in vivo, is reported. With both the PR and ER, evidence for extensive masking in chromatin of many of the acceptor sites is described. The PR and ER acceptor sites appear to be composed of specific acceptor proteins bound to DNA. The dissociation of these proteins from DNA causes a loss of specific binding. Reannealing of these same chromatin protein fractions, but not other protein fractions, back to the DNA reinstates the specific PR binding. Antibodies against the PR acceptors proteins are described. These antibodies block PR but not ER binding to the chromatin acceptor sites, supporting the steroid receptor specific acceptor sites. In the rabbit uterine system, the ER acceptor proteins dissociate from chromatin in three distinct fractions according to their affinity for the DNA. Each of these fractions contains acceptor activity in that each can be reannealed to the DNA to reconstitute specific ER binding sites, i.e. those which are saturable, high affinity, and receptor dependent. Interestingly, the antiestrogen receptor complexes do not bind to one fraction of acceptor proteins which does bind the native estrogen receptor complex. This ER acceptor protein fraction contains two regions of acceptor activity in the molecular mass range of 50,000 and 12,000 daltons. The latter species is in the size range of the PR acceptor proteins. This difference in binding to chromatin acceptor sites by the estrogen receptor, complexed with an estrogen or antiestrogen, may explain the differential regulation of gene expression and the differential biological response to antiestrogens compared to the native estrogens.

Nuclear acceptor sites for sex steroid hormone receptors in chromatin

The steroid receptor interactions in vitro with specific acceptor sites composed of acceptor protein-DNA complexes fulfill many of the criteria of a physiologically significant binding system. Chromatin acceptor sites for many steroid receptors (especially for the progesterone and estrogen receptor) are specific since they are saturable and competitive with unlabelled receptors, have high affinity for the receptor, distinguish between functional and nonfunctional receptors and demonstrate target tissue specificity. Pure DNA as acceptor sites does not display many of these properties. Therefore, it is clear that certain chromatin proteins provide the necessary specificity for the acceptor sites for the steroid receptors. For the progesterone receptor in the chick oviduct, these nuclear sites appear to contain specific chromosomal proteins as well as specific DNA sequences. The substitution of other chromosomal proteins or the genomic DNAs from evolutionarily distant organisms results in a loss of the specific nuclear binding. The nuclear acceptor sites appear to be resistant to the DNase activity which is not characteristic of transcriptionally active domains of the genome. Further studies using the ovalbumin gene sequences from genomic clones also indicate that none of the sequences within this domain and the 3-k flanking regions appear to contain the specific acceptor sequences. These observations have led to development of a model suggesting that the steroid receptors bind to acceptor sites distant from the structural genes the steroids ultimately regulate. Neighboring these acceptor sites are regulatory genes which code for regulatory substances which in turn (as secondary messengers) regulate at great distances the expression of the structural gene. This model might better fit the sex steroids which require 1-2 h to measurably alter gene transcription, as opposed to the glucocorticoids which more rapidly alter gene expression.

Monoclonal antibodies against putative nuclear acceptor sites of the avian oviduct progesterone receptor

Evidence from this and other laboratories has suggested that the nuclear binding sites (acceptor sites) for steroid receptors on chromatin involves chromatin protein-DNA complexes. A saturable high affinity receptor-dependent nuclear binding to these sites by isolated steroid receptor complexes has been reported. Addition of nonradiolabelled progesterone receptor from the chicken oviduct (PRov) successfully competes for the [3H]PRov binding to these acceptor sites in isolated chromatin or in nucleoacidic protein (NAP), a partially deproteinized chromatin enriched in these binding sites. This competition does not occur with pure DNA. This laboratory has isolated and enriched the chromatin proteins (acceptor proteins) involved in the nuclear acceptor sites for the avian oviduct PRov. Monoclonal antibodies against the nuclear acceptor sites for the PRov have been prepared using highly purified hen oviduct acceptor proteins reconstituted to hen DNA. Addition of the MAbs to a cell-free assay blocks PR binding to native oviduct chromatin as well as to NAP. However, the antibodies do not block PR binding to pure DNA nor do they affect the receptor itself. A partial animal species specifically was observed with the Ab inhibition of the PR binding, whereas no tissue specificity was seen. Direct binding of the antibodies to native acceptor sites was demonstrated using an ELISA system. The antibodies showed little recognition of free acceptor protein or DNA alone, indicating specificity for the protein-DNA complex. The partial evolutionary conservation of the nuclear acceptor sites for PR, as shown by the inhibition of PRov binding, was further supported by the partial crossreactivity of the MAbs with the NAPs from the same animal species using the ELISA. These data support earlier studies using PR binding assays showing that: 1) the reconstituted PR acceptor sites resemble the native sites; 2) the sites on whole chromatin and on NAP are similar; 3) the PR binding sites of chromatin and NAP are different from those of pure DNA; and 4) the nuclear acceptor sites for PR are different from those of the estrogen receptor. These results support a receptor specificity of the PR acceptor sites as reported previously using direct receptor competition studies.

Proteins that mask the nuclear binding sites of the avian oviduct progesterone receptor

The binding of a steroid receptor to specific nuclear sites (i.e., nuclear acceptor sites) represents the immediate event preceding the steroid regulation of gene transcription. How the same steroid receptor regulates different genes in different tissues is unknown. Since a major fraction of the nuclear acceptor sites for a variety of steroid receptors has been reported to be masked in the chromatins of a variety of tissues, the differential expression of the nuclear acceptor sites may explain this regulation of different genes. In the avian oviduct, the removal of a subfraction of chromosomal non-histone proteins, termed CP-2, results in the unmasking of the nuclear acceptor sites for the progesterone receptor (PR). Further, the extent of masking of these nuclear acceptor sites for PR has been reported to vary during cytodifferentiation of the avian oviduct. This paper describes a method for the reconstitution of the masking of PR nuclear acceptor sites in the avian oviduct chromatin using a partially purified chromosomal protein fraction (CP-2b). The reannealling of the CP-2b fraction to unmasked avian oviduct chromatin (termed nucleoacidic protein or NAP) results in the "remasking" of about the same number of nuclear acceptor sites for PR as found in intact chromatin. Because some of the PR acceptor sites on the NAP cannot be remasked, these sites either must be protected from masking or not be recognized by the masking proteins. The masking activity apparently involves only protein(s) because the unmasking of acceptor sites can be achieved with protease but not ribonuclease activities and because the dissociated masking activity is destroyed only by proteases. The masking appears to be reversible because the reconstituted masked sites can again be unmasked. Preliminary purification and characterization of the masking activity in fraction CP-2b by molecular sieve chromatography indicate a heterogeneity of size with the activity eluting in a molecular weight range of from 60 000 to greater than 150 000. Whether the masking proteins prevent the binding of the progesterone receptor by directly binding the acceptor sites or by binding neighboring domains to condense the chromatin is unknown. It is speculated that the masking of acceptor sites may be responsible in part for determining the tissue-specific gene expression induced by steroids and/or may play a role in the unresponsiveness of certain human tumors containing steroid receptors.

Preferential binding of estrogen-receptor complex to a region containing the estrogen-dependent hypomethylation site preceding the chicken vitellogenin II gene

DNA-cellulose competition binding assays were used to measure the ability of cloned DNA fragments of the chicken vitellogenin II gene to displace the estrogen-receptor complex from total chicken DNA coupled to cellulose. The DNA fragment that gave the highest competition is situated in the upstream region of the gene between nucleotides -458 and -725. This DNA fragment has four small clusters of A + T-rich sequences and contains the estrogen-dependent hypomethylation site. In vitro methylation of the Msp I site does not change the capacity of the DNA fragment to compete for estrogen-receptor complex, whereas cleavage of the C-C-G-G (Msp I site) results in a complete loss of competition of this fragment for estrogen-receptor complex. These results, combined with deoxyribonuclease I protection experiments, suggest that the most probable binding site for estrogen-receptor complex is . . .G-C-G-T-G-A-C-C-G-G-A-G-C-T-G-A-A-A-G-A-A-C-A-C. . . . This sequence has 73% homology with the core enhancer sequence of simian virus 40, . . .G-G-T-G-T-G-G-A-A-A-G. . . (identical bases italicized).

Human androgen insensitivity mutation does not alter oligonucleotide recognition by the androgen receptor-DHT complex

We studied the binding of dihydrotestosterone-receptor complexes (DHT-R) from human genital skin fibroblasts to oligodeoxyribonucleotides and DNA. Following incubation of fibroblasts with 2 nM [3H]DHT (45 min, 37 degrees C), DHT-R were prepared as total fibroblast sonicates (sonication of cells in 0.5 M KCl), intact fibroblast cytosol (100000 X g supernatant) or intact fibroblast nuclear extract (sonication of nuclei in 0.5 M KCl). DHT-R were also prepared by incubation of fractionated fibroblast cytosol with 4 nM [3H]DHT (4 h, 0 degrees C). Optimal conditions were established for binding of DHT-R from total fibroblast sonicates to oligo-dT cellulose: 60 min, 0 degrees C, low salt (0.05-0.10 M KCl), linearity with DHT-R concentration, and nucleotide saturation. With total fibroblast sonicates the rank order of DHT-R binding was oligo-dT approximately equal to -dG greater than DNA greater than -dC greater than or equal to -dA approximately equal to -dI. Intact fibroblast cytosol displayed a similar preference of DHT-R binding to oligo-dT and -dG but the binding was quantitatively higher than for total fibroblast sonicates, the binding for fractionated fibroblast cytosolic DHT-R formed at 0 degrees C being quantitatively lower. However, binding of DHT-R from cytosol (0 degrees C) to DNA-cellulose was equal to that for DHT-R from cytosol (37 degrees C). Binding of DHT-R from intact fibroblast nuclear extracts was lower than for total fibroblast sonicates. Preparations from cells of patients with receptor-negative, complete androgen insensitivity lacked both DHT-R formation and specific oligonucleotide binding. Binding of oligonucleotides to DHT-R from cells of patients with receptor-positive, complete androgen insensitivity could not be distinguished from that of normal cells. These results suggest: (a) androgen receptor-steroid complexes recognize and bind to certain preferred deoxyribonucleotides; (b) various factors affect the quantitative binding of DHT-R from different cellular preparations to deoxyribonucleotides; and (c) neither qualitative nor quantitative abnormalities for DHT-R of complete androgen-insensitive patients were detectable from oligonucleotide or DNA binding.

A rapid method for analysis of ligand binding to deoxyribonucleic acid and soluble nucleoproteins using streptomycin: application to steroid receptor ligands

A method is described which allows the rapid analysis of the binding of practically any molecules to DNA or to protein--DNA complexes (termed nucleoacidic protein or NAP). The antibiotic streptomycin sulfate, a soluble aminoglycoside, is used to precipitate the DNA after the ligand binding. Comparison of different sources and commercial batches of the antibiotic is described. Optimal conditions for precipitating DNA or NAP and the application of this method to the binding of the chick oviduct progesterone receptor to soluble NAP are described. The streptomycin method can be used with DNA molecules whose size ranges from 750 base pairs to greater than 50 000 base pairs. The method works with a DNA or NAP from a variety of sources, including synthetic homo- or heteropolymers. The precipitation of DNA or NAP by streptomycin occurs rapidly and has minimal effects on the steroid receptor complex or binding of the steroid receptor to DNA or NAP. The requirements and limitations of the method as well as the optimal conditions for binding of the progesterone receptor to DNA or NAP are described.

Current concepts: II. Hormonal regulation of molecular events during aging

This review is an attempt to establish a role for both glucocorticoid and thyroid hormones in the aging process as factors which mediate the regulation of transcription and translation of specific genetic domains. Furthermore, through a review of the current knowledge of the effect of long-term hypophysectomy on physiological and biochemical functions which change with age in the rat an attempt has been made to establish a role for a pituitary factor in the regulation of the aging process through an affect on transcription and translation of hormonally induced genetic domains. Although we can propose a possible mechanism of action of this factor, the proposal is premature and requires extensive systematic testing. It will be interesting to carefully consider the possible relationship, if any, of this pituitary factor to the effects of dietary restriction on animal longevity. How this pituitary-aging interaction might be exploited is open to speculation but it is certainly worth further consideration based on evidence currently at hand.

Problems associated with dose response in steroid-hormone activation of structural genes

A typical target cell for a sex steroid hormone contains 10 000--20 000 specific high-affinity receptors for that hormone. However full physiological responses can be achieved with only 2000 of these receptors involved in hormone--receptor complex interaction with the nucleus. The number of nuclear acceptor sites that must be filled before responses occur maybe even less. This implies that multiple occupation of nuclear acceptor sites by hormone--receptor may occur permitting co-operative induction of transcription of selected genes. The numbers of sites of initiation of RNA synthesis seem excessively high (about 70 000 per cell). Although this may be an artifact of the isolation procedures the proportion of initiation sites under hormonal control (equivalent to about 30 000 per cell) is still large. The numbers of mRNA species under hormonal control varies greatly depending on the particular hormone and target tissue. The extent to which these different observations can be incorporated into a unifying theory is discussed.

Identification of biologically active and inactive steroid receptors

Steroids enter target cells and bind to specific receptor proteins. These complexes translocate to the nuclei, bind to the chromatin, and alter gene expression. Recently, inactive progesterone receptors of the chick oviduct have been identified in this laboratory during the late winter which are not capable of translocating and binding to nuclear acceptor sites either in vivo or in a cell free assay. During this period the oviduct remains unresponsive to the steroid. The nuclear binding activity does return at the end of the season with a corresponding return of oviduct responsiveness to the steroid. Analysis of the active and inactive receptors of progesterone reveals no difference in sedimentation rates in high salt or in the affinity of the steroid for the receptor. The tissue levels of the inactive receptor, however, are about-one-half those of the active receptor. Quantitative analysis of the molecular species of the progesterone receptor separated by isoelectric focusing reveals two species for the active receptor preparations (an A species focusing at a pH of 7 and a B species focusing at a pH of 6). The A species was absent in the active receptor preparations which explains the lower amounts of total receptor in this group. Further studies have shown inactive progesterone receptors in the undeveloped oviducts and in the oviducts of estrogen withdrawn chicks. In these instances, the B species of the receptor is missing. The results suggest: (1)a novel regulation of steroid action may exist which acts by modulating the levels of one of the two receptor species (or possible subunits of a dimer); (2)the presence of a steroid receptor does not necessarily reflect that the receptor is functional; and (3)the biological activity of a steroid may be assessed via cell free nuclear binding assays or via analysis of the molecular species.

Factors affecting the binding of chick oviduct progesterone receptor to deoxyribonucleic acid: evidence that deoxyribonucleic acid alone is not the nuclear acceptor site

Studies on the interaction of the chick oviduct progesterone-receptor complex (P-R) with various nuclear components revealed a variable, nonsaturable binding of P-R to pure deoxyribonucleic acid (DNA). In contrast, a receptor-dependent, saturable, high level of binding of P-R was observed with a nonhistone protein-DNA complex called nucleoacidic protein (NAP). Three categories of factors were identified which affected the binding of P-R to the DNA. These were (1) the conditions of the binding assay, (2) the properties of the receptor, and (3) the state of the DNA. The conditions in the binding assay which affect DNA binding are the choice of the blanks, the salt concentration, and the pH of the assay. The receptor preparations display their own characteristic levels of binding to native DNA. The basis of this DNA binding capacity by each preparation is unknown. Lastly, the purity and the integrity of the DNA itself determine the level of binding of the P-R. Protein impurities, moderate degradation of the DNA by enzymatic or physical fragmentation, and ultraviolet (UV) light treatment greatly enhance the receptor binding to the DNA. The extent of binding to DNA depends on the degree of damage. Interestingly, totally denatured (single-stranded) DNA displays little or no binding of the P-R. Seasonal differences which are observed for the binding of P-R to chromatin in vivo and in vitro and to NAP in vitro do not occur with DNA whether it is undamaged or damaged. It is concluded from these studies that under controlled conditions and by using DNA preparations as native as possible, minimal binding of P-R to pure DNA occurs. The numerous reports in the literature describing marked binding of the steroid-receptor complex to DNA may well be due to conditions described in this paper. Further, it is concluded that native or partially degraded DNA alone does not appear to represent the native nuclear acceptor sites for the chick oviduct P-R. In contrast, the DNA-nonhistone protein (acceptor protein) complexes do show characteristics of the native-like acceptor sites.

Circannual rhythms in progesterone receptor levels and functions

Studies in this laboratory on the nuclear binding sites (acceptors) for progesterone receptor in the developed chick oviduct have resulted in the detection of seasonal variations in the levels and functions of the receptor. Cytosol preparations obtained from the chick oviducts during the winter/spring period between January and May display reduced receptor levels as well as a loss of the capacity of the receptor to bind to nuclear "acceptor" sites in vitro. The binding of [3H]P-R to whole chromatin or purified acceptor proteins reannealed to DNA display the same rhythm. No such rhythm is detected for the binding of P-R to pure DNA. Computer analysis of the data, using least squares method to fit the data to cosine curves, shows a significant fit indicating a circannual rhythm in P-R binding to the acceptor protein-DNA complex but not to pure DNA. The nuclear binding in vivo, achieved by injecting [3H]progesterone into the wing vein and analyzing the radioactivity localized in the oviduct nuclei, also displays a similar rhythm. These results support that native nuclear acceptor sites for progesterone in the chick oviduct represent protein-DNA complexes and not pure DNA. The failure of P-R to bind the nuclear acceptor sites in vivo and in vitro during this period can be explained by the two subunit hypothesis of Schrader and O'Malley, whereby one of the two subunits is absent or inactive during this period.

Factors influencing association of glucocorticoid receptor-steroid complexes with nuclei, chromatin, and DNA: interpretation of binding data

Attempts to reconstruct, in a test tube, the steroid-hormone system of a responsive cell are fraught with enumerable difficulties. In this chapter I have attempted to point out some of the factors that affect receptor-steroid complexes and their interactions with acceptors. In most cases there is a quantitative influence of these factors on the level of steroid complex binding to acceptors. In some cases, selected experimental designs that neglect these factors and methods of presenting the observed data may lead to artifactual conclusions. Several of these problems should disappear when the prospect of pure receptor-steroid complexes [127, 147, 150, 181, 247, 248] becomes a common occurrence. Nevertheless much has already been learned about the interactions of complexes with acceptors, which in turn have been used to help formulate models of steroid-hormone action.

Studies on sex-organ development. Changes in chemical composition and oestradiol-binding capacity in chromatin during the differentiation of chick Müllerian ducts

Biochemical and immunochemical techniques were used to probe the changes in composition of the chromatin of differentiating Müllerian ducts. The non-histone protein increases gradually in the left duct and reaches a constant amount at day 15 of incubation, then remains at the same value until after birth. In the regressing right duct, the non-histone protein increases and then decreases. Gel electrophoresis indicated an increased heterogeneity in the composition of the non-histone protein corresponding to Müllerian-duct differentiation. Little variation in quantity and quality of the histone was observed; however, immunochemical assay confirmed the structural change of Müllerian-duct chromatin during development. An antibody against the chromatin of the newborn-chick oviduct was produced in the rabbit. The chromatin of Müllerian ducts from the early embryonic stage showed a small affinity with the antibody; the affinity increased during the late embryonic stages. The affinity was greatly decreased in the regressing right duct. Oestrogen-binding sites were present in the chromatin of the left and right Müllerian ducts during differentiation, with more sites in the left duct than in the right one during the late stages of development. After oestrogen treatment in vivo, the oestrogen-binding sites on the chromatin of both the left and the right ducts were increased, with a greater increase in the left duct than in the right. In the developing left duct the binding sites reach a maximum on day 15 of incubation, and remain constant at that value until birth.

Binding of estradiol receptor complexes to isolated human breast chromatin

The interaction of estradiol-receptor complexes and isolated human breast tumor chromatin was studied under equilibrium conditions. The estradiol-receptor complexes bound specifically to the chromatin of hormone dependent tumors and showed a single class of binding sites with a Ka of 0.96 X 10(10) M-1 and a binding capacity of 1.5 pmoles/mg DNA. The binding was a temperature-dependent process and involved a "transformation" of the receptor protein. The heat-activated hormone-receptor complex was more active than the 8S form in the binding phenomenon. The specific interaction of estradiol-receptor complex with isolated chromatin was saturable and sensitive to conditions of temperature and ionic strength. Furthermore under optimal conditions no acceptor sites were detected in chromatin of hormone independent tumors.